We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01405300
First Posted: July 29, 2011
Last Update Posted: June 24, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Peanut Institute
Information provided by (Responsible Party):
Penny Kris-Etherton, Penn State University
  Purpose
Pilot study data have demonstrated that peanuts ameliorate the postprandial glucose and insulin response when incorporated into an acute high fat/high glucose meal. However, it is unclear whether acute consumption of peanuts can also influence vascular function. This study will therefore evaluate the effects of acute peanut consumption on vascular function, glycemic control, and plasma lipids. The hypothesis is that that addition of peanuts to a high fat/high glucose meal will reduce the production of triglycerides, glucose, and improve endothelial function as measured by flow-mediated dilation (FMD).

Condition Intervention Phase
Cardiovascular Disease Dietary Supplement: Control Dietary Supplement: Peanut Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function

Resource links provided by NLM:


Further study details as provided by Penny Kris-Etherton, Penn State University:

Primary Outcome Measures:
  • Change from baseline in Flow-Mediated Dilation at 4 hours postprandial [ Time Frame: 0 min; 240 min ]

Secondary Outcome Measures:
  • Change from baseline in oxidative stress over 4 hours postprandial [ Time Frame: 0 min, 30 min, 60 min, 120 min, 240 min ]
  • Change from baseline in serum lipids over 4 hours postprandial [ Time Frame: 0 min, 30 min, 60 min, 120 min, 240 min ]
  • Change from baseline in serum glucose over 4 hours postprandial [ Time Frame: 0 min, 30 min, 60 min, 120 min, 240 min ]
  • Change from baseline in serum insulin over 4 hours postprandial [ Time Frame: 0 min, 30 min, 60 min, 120 min, 240 min ]

Estimated Enrollment: 20
Study Start Date: August 2011
Study Completion Date: June 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Peanut Dietary Supplement: Peanut
34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver ~1200 kcal.
Placebo Comparator: Control Dietary Supplement: Control
34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver ~1200 kcal.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 20-50 years of age
  • LDL-C below 160 mg/dL
  • Triglyceride below 350 mg/dL
  • Blood pressure within normal ranges (below 140/90 mmHg)
  • Not taking medication for elevated lipids, blood pressure or glucose

Exclusion Criteria:

  • Allergies to peanuts or dairy products
  • Known intolerance for high fat meals
  • History of cardiovascular disease (CVD), kidney disease, diabetes or inflammatory diseases such as GI disorders and arthritis
  • Use of non-steroidal anti-inflammatories or immunosuppressants
  • Conditions requiring the use of steroids
  • Use of medication or supplements for elevated lipids, blood pressure or glucose
  • Donation of blood or plasma during the study
  • History of thyroid disease
  • Women
  • Lactose intolerance
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01405300


Locations
United States, Pennsylvania
Penn State University
University Park, Pennsylvania, United States, 16802
Sponsors and Collaborators
Penn State University
Peanut Institute
Investigators
Principal Investigator: Penny M Kris-Etherton, PhD, RD Penn State University
Study Director: Ann C Skulas-Ray, PhD Penn State University
Study Director: Xiaoran Liu Penn State University
  More Information

Responsible Party: Penny Kris-Etherton, Distinguished Professor of Nutrition, Penn State University
ClinicalTrials.gov Identifier: NCT01405300     History of Changes
Other Study ID Numbers: PKE PPNUT
First Submitted: July 27, 2011
First Posted: July 29, 2011
Last Update Posted: June 24, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Cardiovascular Diseases